Dyadic International (DYAI) Competitors $0.96 -0.02 (-2.28%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.11%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. TARA, CRBP, OTLK, COYA, IOBT, EQ, ADAG, BMEA, ANEB, and MGNXShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Protara Therapeutics (TARA), Corbus Pharmaceuticals (CRBP), Oncobiologics (OTLK), Coya Therapeutics (COYA), IO Biotech (IOBT), Equillium (EQ), Adagene (ADAG), Biomea Fusion (BMEA), Anebulo Pharmaceuticals (ANEB), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Its Competitors Protara Therapeutics Corbus Pharmaceuticals Oncobiologics Coya Therapeutics IO Biotech Equillium Adagene Biomea Fusion Anebulo Pharmaceuticals MacroGenics Protara Therapeutics (NASDAQ:TARA) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has stronger valuation & earnings, TARA or DYAI? Dyadic International has higher revenue and earnings than Protara Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.62-1.96Dyadic International$3.49M9.92-$5.81M-$0.19-5.04 Does the media prefer TARA or DYAI? In the previous week, Protara Therapeutics had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Protara Therapeutics and 2 mentions for Dyadic International. Dyadic International's average media sentiment score of 1.00 beat Protara Therapeutics' score of 0.86 indicating that Dyadic International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TARA or DYAI more profitable? Protara Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -134.84%. Protara Therapeutics' return on equity of -36.87% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.87% -33.85% Dyadic International -134.84%-355.39%-60.66% Do analysts rate TARA or DYAI? Protara Therapeutics currently has a consensus price target of $19.60, indicating a potential upside of 518.30%. Dyadic International has a consensus price target of $6.00, indicating a potential upside of 527.02%. Given Dyadic International's higher possible upside, analysts plainly believe Dyadic International is more favorable than Protara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in TARA or DYAI? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 8.4% of Protara Therapeutics shares are held by insiders. Comparatively, 29.5% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, TARA or DYAI? Protara Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. SummaryProtara Therapeutics beats Dyadic International on 10 of the 16 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.44M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-5.0420.8978.4326.42Price / Sales9.92458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book11.969.9310.916.06Net Income-$5.81M-$53.38M$3.29B$266.28M7 Day Performance5.46%0.05%0.01%-0.76%1 Month Performance-5.26%7.08%7.06%3.83%1 Year Performance-24.65%11.92%50.09%24.39% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International3.4821 of 5 stars$0.96-2.3%$6.00+527.0%-25.3%$35.44M$3.49M-5.047Positive NewsShort Interest ↓Gap DownTARAProtara Therapeutics2.5014 of 5 stars$3.05-1.9%$19.60+542.6%+68.2%$119.99MN/A-1.8830CRBPCorbus Pharmaceuticals3.7973 of 5 stars$9.89+1.0%$49.00+395.4%-82.3%$119.98MN/A-2.0840OTLKOncobiologics2.5145 of 5 stars$2.97+10.8%$9.60+223.2%-86.8%$119.05M$1.51M-5.2120Options VolumeGap UpHigh Trading VolumeCOYACoya Therapeutics2.6856 of 5 stars$6.50-5.2%$16.50+153.8%+9.3%$114.73M$3.55M-5.246News CoverageAnalyst ForecastGap UpHigh Trading VolumeIOBTIO Biotech2.3399 of 5 stars$1.71-1.7%$8.67+406.8%+75.0%$114.63MN/A-1.0830Short Interest ↑EQEquillium0.5151 of 5 stars$1.90flat$1.00-47.4%+92.6%$113.06M$16.55M-3.3940News CoverageShort Interest ↑ADAGAdagene3.0723 of 5 stars$2.35-1.7%$7.00+197.9%-27.6%$112.59M$100K0.00260News CoverageShort Interest ↓BMEABiomea Fusion3.4157 of 5 stars$1.81-1.1%$16.80+828.2%-73.7%$108.90MN/A-0.6050ANEBAnebulo Pharmaceuticals1.9678 of 5 stars$2.70+3.8%$5.50+103.7%+35.9%$106.82MN/A-10.384Gap DownMGNXMacroGenics4.0569 of 5 stars$1.64-3.0%$3.60+119.5%-41.8%$106.82M$149.96M-2.88430 Related Companies and Tools Related Companies Protara Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Oncobiologics Alternatives Coya Therapeutics Alternatives IO Biotech Alternatives Equillium Alternatives Adagene Alternatives Biomea Fusion Alternatives Anebulo Pharmaceuticals Alternatives MacroGenics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
